Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study

14 Jul 2023

Abstract excerpt

Data on outcome of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for patients with large B-cell lymphoma (LBCL) with secondary central nervous system (CNS) involvement (SCNSL) are limited.In this study, we present results of CD19 CAR-T therapy for relapsed/refractory SCNSL in a German multicenter real-world cohort, a collaborative effort of the German Lymphoma Allianz (GLA) and the German Stem...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 37450376
DOI: 10.1182/bloodadvances.2023010336

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST studyPMID 37450376Read ↗

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaSemantic proximity Read ↗

CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experienceSemantic proximity Read ↗

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaSemantic proximity Read ↗

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read ↗

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.Semantic proximity Read ↗

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read ↗

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The NetherlandsSemantic proximity Read ↗

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.Semantic proximity Read ↗

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapseSemantic proximity Read ↗

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Chimeric Antigen Receptor‐T Cell TherapySemantic proximity Read ↗

Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.